Patents by Inventor Carlos E. A. Monti

Carlos E. A. Monti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5614536
    Abstract: Substituted N-aminoalkylmethane sulfanilide of formula (I), their solutions and pharmaceutically acceptable addition salts, their pharmaceutical compositions and their therapeutic use. In formula (I) Y represents hydrogen, cyano, nitro, amino, acetamide or halogen; n is an integer between 2 and 4, R.sup.1 and R.sup.2 equal or different are alkyl-(C1-C4) or they are connected together and with the N-atom thereby forming a 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-methyl-1-piperazinyl, 4-ethylpiperazinyl, 4-propylpiperazinyl, 1-homopiperidinyl or 4-morpholine residue. The products of formula (I) are used as antispasmodic agents.
    Type: Grant
    Filed: January 7, 1994
    Date of Patent: March 25, 1997
    Assignee: Roemmers S.A.I.C.F.
    Inventors: Carlos E. A. Monti, Gustavo E. Aldom a
  • Patent number: 5574170
    Abstract: The present invention concerns compounds of formula (I) which is the novel 2-(1-pyrrolidinyl)ethylester of (.+-.)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxyl- or ketorolac-acid, the pharmaceutically acceptable addition salts thereof, preferably oxalate. It is known that the commercially available ketorolac (trometamole salt) exhibits undesired side effects (gastrointestinal irritation and ulceration). Surprisingly, when applying the compounds according to the invention there are considerably less undesired effects which render them potentially of great advantage as analgetic/antiphlogistic agent.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 12, 1996
    Assignee: Roemmers S.A.I.C.F.
    Inventors: Carlos E. A. Monti, Gustavo E. Aldoma
  • Patent number: 5508301
    Abstract: The present invention concerns compounds of formula (I) which is the novel 2-(1-pyrrolidinyl)ethylester of (.+-.)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxyl- or ketorolac-acid, the pharmaceutically acceptable addition salts thereof, preferably oxalate. It is known that the commercially available ketorolac (trometamole salt) exhibits undesired side effects (gastro-intestinal irritation and ulceration). Surprisingly, when applying the compounds according to the invention there are considerably less undesired effects which render them potentially of great advantage as analgetic/antiphlogistic agent.
    Type: Grant
    Filed: January 7, 1994
    Date of Patent: April 16, 1996
    Assignee: Roemmers S.A.I.C.F.
    Inventors: Carlos E. A. Monti, Gustavo Enrique Aldoma